SNCA / alpha-Synuclein Protein (Native)

Synuclein, alpha (non A4 component of amyloid precursor) Protein Datasheet

SNCA / α-Synuclein Protein Product Information

• Synonym: NACP, PARK1
• Protein Construction: A DNA sequence encoding the mature form of human SNCA isoform 1 (P37840-1) (Met 1-Ala 140 ) was expressed and purified.
• Source: Human
• Expression Host: E.Coli

SNCA / α-Synuclein Protein QC Testing

• Purity: > 97 % as determined by SDS-PAGE.
• Endotoxin: Please contact us for more information.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Met 1
• Molecular Mass: The recombinant human SNCA consisting of 140 amino acids and has a calculated molecular mass of 14.5KDa. It migrates as an approximately 19KDa band in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile PBS, pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: SNCA / α-Synuclein protein

SNCA / α-Synuclein Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

SNCA / α-Synuclein Protein Description

α-Synuclein(α-Syn) exists as at least two structural isoforms: a helix-rich, membrane-bound form that both the N- and C-terminal regions of α-synuclein are tightly associated with membranes and a disordered, cytosolic form. It has been showed thatα-Synuclein was highly expressed in the mitochondria in olfactory bulb, hippocampus, striatum, and thalamus, where the cytosolicα-Synuclein was also rich. Normally the unstructured soluble type of alpha-synuclein can aggregate to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. α-Synuclein abnormality and mitochondrial deficiency are two major changes in the brain of patients with Parkinson's disease (PD). In addition, α-synuclein is an abundant component of Lewy bodies in sporadic Parkinson's disease and diffuse Lewy body disease.

References

1. Arima K. et al., 1998, Brain Res. 808 (1): 93-100.
2. Arima K. et al., 1998, Acta Neuropathol. 96 (5): 439-44.
3. Lee HJ. et al., 2001, The Journal of Biological Chemistry. 277: 671-8.